Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:20:50.904Z.
Calculation as of: 2026-10-06T14:20:50.904Z.
Quote observation: 2026-10-06T14:20:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 271c6898cd70d4c389427987313f1838723d439a48fe58857c9b6a6cb9daa9ad
PE RATIO
N/A
Market Cap
$598.37M
PE Ratio
4.74
TTM Avg
17.55
3Y Avg
51.19
5Y Avg
25.53
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aura Biosciences, Inc. (AURA) | $633.55M | N/A | N/A | N/A | N/A |
| Climb Bio, Inc. (CLYM)vs › | $623.59M | N/A | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $647.18M | N/A | N/A | N/A | N/A |
| Fulgent Genetics, Inc. (FLGT)vs › | $604.37M | N/A | 4.23 | 40.60 | 40.60 |
| AngioDynamics, Inc. (ANGO)vs › | $614.61M | N/A | 43.31 | 43.31 | 89.76 |
| Helus Pharma Inc. (HELP)vs › | $659.20M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $659.47M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $666.04M | 114.24 | 37.43 | 206.22 | 206.22 |
| Ironwood Pharmaceuticals, Inc. (IRWD)vs › | $598.37M | 4.74 | 17.55 | 51.19 | 25.53 |
| Faeth Therapeutics, Inc. (FTH)vs › | $679.27M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$6.13
Forward EPS (Est.)
$-1.67
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
